Our promise to you:
Guaranteed product quality, expert customer support.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
CDK4 Gene Editing 
CDK4 (Cyclin-dependent kinase 4), also known as cell division protein kinase 4, is a member of the cyclin-dependent kinase family, a class of Ser/Thre protein kinases. CDK4 is a key regulator of the G1-S transition in the cell cycle. Cyclin D1 (CCND1) forms a complex with CDK4 and phosphorylates retinoblastoma (Rb) protein, thereby inactivating it. Unphosphorylated Rb binds and inhibits the function of the E2 family (E2F) transcription factor. After phosphorylation, Rb dissociates from the E2F transcription factor, enabling them to participate in DNA replication and cell division. The progress of CDK4 phosphorylating Rb and driving cell cycle progression is inhibited by p16. Deregulation of the cyclin D-CDK4/6-INK4-Rb pathway is frequently observed in cancer and leads to cell cycle progression and sustained growth.
Mutations in this gene and its related proteins, including D-type cyclins, p16 (INK4a), CDKN2A and Rb, have been found to be involved in the development of a variety of cancers. Today, dysregulated CDK4 is considered a potential therapeutic target for certain cancer types, and various CDK4 inhibitors are being tested for cancer treatment in clinical trials.
Figure 1: Schematic representation of the CDK4/6-Rb pathway (Pan, Qi. 2017)
CDK4 Gene Editing Service
CRISPR/Cas9 PlatformCB, a global leading biotechnological company specializing in gene editing, is dedicated to offering comprehensive CRISPR/Cas9 gene editing services and products to a wide range of genomics researchers. With deep gene editing knowledge and extensive experience in experimental operation and data processing, we can help you effectively control target genes deleted, inserted or point mutated in cells or animals via CRISPR/Cas9 technology.
- CDK4 Gene Editing Cell Line Generation
We have successfully implemented CDK4 CRISPR/Cas9 gene edited in both easy-to-transfect cell lines and hard-to-transfect cells. To support your projects, we will offer you full-length custom CDK4 gene editing service from strategy design to final stable cells. Our CDK4 gene editing cell line generation services include:
➢ gRNA design and synthesis
➢ Transfect the cell lines you're interested
➢ Select the high expression cells and sort monoclonal cell
➢ Validate the knockout/knockin/point mutation of CDK4 by PCR and sequencing
➢ Produce cryogenic preserved vials of stable cells and a final report
Typically, we develop CRISPR-mediated gene editing cell lines including HEK239T, Hela, HepG2, U87, but we can use other cell lines according to your requirements.
- Alternative cell lines
➢ Blood Lineage Cells (RAW264.7, HMC1.2, K562, U937 etc.)
➢ Cancer Cell Lines (HEK293, HEK293T, Hela, MCF7, Neuro2a, HepG2, U87 etc.)
➢ Stem Cells (iPSC)
➢ Other Cell Lines (NIH3T3, MCF10, HEME, SW10 etc.)
- CDK4 Gene Editing Animal Model Generation
CRISPR/Cas9 PlatformCB also has extensive experience in incorporating CRISPR/Cas9 technology into animal models, which have been fully recognized by our clients. Tell us your needs, we provide a one-stop-shop CDK4 CRISPR/Cas9 gene editing animal service and guarantee at least 2 founders or 3 F1 animals with shorter turnaround time and lower price. Our CDK4 gene editing animal model generation services include:
➢ CDK4 gene conventional knockout animals
➢ CDK4 gene conditional knockout animals
➢ CDK4 point mutation animals
➢ CDK4 knockin animals
Alternative species: mouse, rat, rabbit, zebrafish, C. elegans, etc.
CRISPR/Cas9 PlatformCB is devoted to providing the best gene editing services and products for academic research, biotech research and pharmaceutical drug discovery with excellent quality management and quality assurance capacity. To accelerate the achievement of your research goals, our gene editing expert team provides you with custom CRISPR/Cas9 services for any specific gene to help you solve problems encountered during your research. There is no doubt that CRISPR/Cas9 PlatformCB will be your best partner to support your research.
Related Products at CRISPR/Cas9 PlatformCB
| CATALOG NO. | PRODUCT NAME | INQUIRY |
| CLKO-1819 | CDK4 KO Cell Lysate-HeLa | Inquiry |
| CSC-RT1960 | CDK4 Knockout Cell Line-HeLa | Inquiry |
References
- Erika Hamilton & Jeffrey R. Targeting CDK4/6 in patients with cancer. Cancer Treatment Reviews. 2016; 45:129–138.
- Mark A. Dickson. Molecular Pathways: CDK4 Inhibitors for Cancer Therapy. Clinical Cancer Research. 2014; 20(13). 3379-3383.
- Sheppard, K. E. et al. The Cell-Cycle Regulator CDK4: An Emerging Therapeutic Target in Melanoma. Clinical Cancer Research. 2013; 19(19):5320–5328.
- Sobhani. et al. Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer. Cell. 2019; 8(4):321.
- Pan, Qi. et al. CDK4/6 Inhibitors in Cancer Therapy: A Novel Treatement Strategy for Bladder Cancer. Bladder Cancer. 2017; 3(2):79-88.